RSNA 2014 

Abstract Archives of the RSNA, 2014


SSJ20-01

18F-FDG PET: An Independent Prognostic Biomarker in Idiopathic Pulmonary Fibrosis

Scientific Papers

Presented on December 2, 2014
Presented as part of SSJ20: Nuclear Medicine (SPECT/CT and Inflammation Imaging)

Participants

Thida Win, Abstract Co-Author: Nothing to Disclose
Nicholas J. Screaton BMBCh, Abstract Co-Author: Nothing to Disclose
Joanna C. Porter PhD, FRCP, Abstract Co-Author: Advisor, Onyx Pharmaceuticals, Inc Advisor, InterMune, Inc
Balaji Ganeshan PhD, Presenter: Scientific Director, TexRAD Limited
Lynn Millner, Abstract Co-Author: Research funded, GlaxoSmithKline plc
Ashley McAllister Groves MBBS, Abstract Co-Author: Investigator, GlaxoSmithKline plc Investigator, General Electric Company Investigator, Siemens AG

PURPOSE

There is a lack of prognostic biomarkers for patients with Idiopathic Pulmonary Fibrosis (IPF). The purpose of this study was to investigate the potential of 18F-FDG PET/ CT as a predictor of survival in patients with IPF.

METHOD AND MATERIALS

A total of 53 (46 male, 7 female; mean age 76±9.3 years) prospectively and consecutively consented IPF patients were recruited for 18F-FDG PET/CT. Baseline FVC and TLCO were performed. The maximum pulmonary uptake of 18F-FDG (SUVmax), the background lung activity (SUVmin,) and target-to-background ratio (TBR SUVmax/ SUVmin) were quantified. Kaplan-Meier survival analysis assessed the performance of these biomarkers as survival risk classifiers.   

RESULTS

Mean duration of follow-up was 26.8±18.1-months. There were 17 deaths. FVC (p=0.003), TLCO (p=0.019), SUVmin (p=0.021), TBR (p=0.028) were associated with mortality. Combining SUVmax with both either FVC or TLCO was synergistic (p<0.001 and p<0.011 respectively). Combining TBR with TLCO was also synergistic (p=0.001). Cox Regression showed SUVmin to be an independent survival factor in IPF patients.

CONCLUSION

Measurements of pulmonary uptake of 18F-FDG quantified using PET is associated with mortality in patients with IPF.

CLINICAL RELEVANCE/APPLICATION

18F-FDG PET/CT has potential to risk starifty patients with IPF 

Cite This Abstract

Win, T, Screaton, N, Porter, J, Ganeshan, B, Millner, L, Groves, A, 18F-FDG PET: An Independent Prognostic Biomarker in Idiopathic Pulmonary Fibrosis.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14013876.html